Skip to main content
All lobbying filings

CENTER FOR INDIVIDUAL FREEDOM

Lobbying for CENTER FOR INDIVIDUAL FREEDOM

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 20, 2026
Expenses
$20,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Virginia

Official filing document

 Government bodies contacted 6

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 9

Correspondence in general opposition to any export controls on refined petroleum products, including any diesel export ban; research relating thereto.

S. 1414 - Expedited Access to Biosimilars Act Correspondence with United States Senate in opposition to the legislation, which would weaken standards of interchangeability studies by reducing Food and Drug Administration (FDA) discretion regarding interchangeability determinations, thereby reducing competition in the realm of complex biologics and lowering applicable standards for substituting biosimilars relative to generics; research relating thereto. ------------------- H.R. 9599 - SECURE 340B Act Correspondence with United States Senate in support of the legislation to reform the 340B Drug Pricing Program and restore its focus back toward the vulnerable patients whom Congress originally intended it to serve; research relating thereto. ------------------- Correspondence with United States Senate Committee on Finance urging opposition toward artificial government pharmaceutical price controls, in support of ensuring that fairly negotiated savings actually reach patients, in favor of reducing unnecessary barriers to treatments, in support of facilitating legitimate generic and biosimilar competition, in support of biomedical research and retention of scientific talent and protection of strong patent and other intellectual property (IP) rights; research relating thereto.

H.R. 928 - Railway Safety Act Correspondence with United States Senate in opposition to any effort to include the Railway Safety Act of 2025 (H.R. 928) as part of surface transportation reauthorization; research relating thereto.

Correspondence urging the United States Federal Communications Commission to avoid intervening, either directly or indirectly, in affiliation agreements freely negotiated between broadcast networks and local television station owners; research relating thereto.

Correspondence with United States Federal Reserve System Board of Governors urging general opposition to blocking bank license applications of fintech lenders; research relating thereto.

S. 252 - Guidance Out of Darkness Act H.R. 1515 - Guidance Out of Darkness Act Correspondence with United States Senate urging passage of the legislation, which would require federal administrative agencies to publish their guidance documents online; research relating thereto.

H.R. 2918 - Family Business Legacy Act of 2025 Correspondence with United States Senate and United States House of Representatives urging inclusion of the Family Business Legacy Act of 2025 (H.R. 2918) in future reconciliation or tax-related legislation; research relating thereto. -------------- Correspondence with United States Treasury Dept. and United States House of Representatives generally urging full enforcement of foreign-entity restrictions enacted through the One Big Beautiful Bill Act and prevent Chinese-controlled battery companies from accessing American manufacturing and energy tax incentives, including the Section 45X Advanced Manufacturing Production Credit and the Section 48E Clean Electricity Investment Credit, through U.S. subsidiaries, contractual arrangements or nominally domestic operations; research relating thereto.

H.R. 9453 - End EPA Abuse Act of 2026 S. 4931 - End EPA Abuse Act of 2026 Correspondence with United States Senate and United States House of Representatives in support of the legislation to rein in federal environmental overregulation and Environmental Protection Agency (EPA) overreach; research relating thereto. ------------------- H.J. Res. 202, 205, 210, 212, 213, 214; S.J. Res. 205, 206, 207, 208, 209, 210 Correspondence with United States Senate and United States House of Representatives in support of Congressional Review Act (CRA) resolutions of disapproval targeting Environmental Protection Agency (EPA) Clean Air Act preemption waivers granted to California (H.J. Res. 202, 205, 210, 212, 213, 214; S.J. Res. 205, 206, 207, 208, 209, 210); research relating thereto. ------------------- H.R. 7502 - Recycled Materials Attribution Act Correspondence with United States House of Representatives in support of the legislation, which would replace state and local recycling rules with a single and clear federal standard governing recycling claims; research relating thereto.

H.R. 5267 - American Franchise Act Correspondence with United States House of Representatives in support of the legislation that would amend federal law to define joint employer to include only franchisors that exercise substantial, direct and immediate control over essential terms of employment such as hiring, firing, wages, scheduling and supervision; research relating thereto.

 Bills named in this filing 12
  • S. 1414
    Expedited Access to Biosimilars Act
  • H.R. 9599
    SECURE 340B Act
  • H.R. 928
    Railway Safety Act of 2025
  • S. 252
    GOOD Act
  • H.R. 1515
    GOOD Act
  • H.R. 2918
    Family Business Legacy Act of 2025
  • H.R. 9453
    End EPA Abuse Act of 2026
  • S. 4931
    End EPA Abuse Act of 2026
  • H.J. Res. 202
    Providing congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Enviro…
  • S.J. Res. 205
    A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule …
  • H.R. 7502
    Recycled Materials Attribution Act of 2026
  • H.R. 5267
    American Franchise Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem